MAIA Biotechnology Inc (MAIA)
3.28
+0.16
(+5.13%)
USD |
NYAM |
May 17, 16:00
3.28
0.00 (0.00%)
After-Hours: 20:00
MAIA Biotechnology Cash from Financing (Quarterly): 4.717M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.717M |
| December 31, 2023 | 5.025M |
| September 30, 2023 | 0.1259M |
| June 30, 2023 | 4.120M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | -0.1929M |
| September 30, 2022 | 10.26M |
| Date | Value |
|---|---|
| June 30, 2022 | -0.1202M |
| March 31, 2022 | 2.531M |
| December 31, 2021 | 1.229M |
| September 30, 2021 | 5.483M |
| June 30, 2021 | 4.892M |
| March 31, 2021 | 2.430M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1929M
Minimum
Dec 2022
10.26M
Maximum
Sep 2022
3.115M
Average
2.531M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 0.999M |
| Avid Bioservices Inc | 0.085M |
| Oragenics Inc | -0.1806M |
| NeuBase Therapeutics Inc | -0.1745M |
| Viking Therapeutics Inc | 606.04M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.587M |
| Free Cash Flow | -13.30M |
| Free Cash Flow Per Share (Quarterly) | -0.2038 |
| Free Cash Flow Yield | -26.94% |